
## Sebastien Calbo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9268512/publications.pdf Version: 2024-02-01



| # | Article  | IF   | CITATION |
|---|--|------|----------|
| 1 | The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is<br>Predictive of Relapses After Treatment With Rituximab. Frontiers in Immunology, 2022, 13, 849790.   | 4.8  | 1        |
| 2 | FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2<br>Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. Frontiers in Immunology, 2022,<br>13, .                          | 4.8  | 9        |
| 3 | Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T<br>Follicular Helper Cells in Pemphigus. Journal of Investigative Dermatology, 2021, 141, 2132-2140.e1.   | 0.7  | 13       |
| 4 | Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment. Biomedicines, 2021, 9, 1411.   | 3.2  | 1        |
| 5 | Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After<br>Treatment With Rituximab or a Standard Corticosteroid Regimen. Frontiers in Immunology, 2019, 10,<br>1794.                              | 4.8  | 20       |
| 6 | First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment<br>of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet,<br>The, 2017, 389, 2031-2040. | 13.7 | 438      |
| 7 | Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response. Science Translational Medicine, 2013, 5, 175ra30.  | 12.4 | 200      |